Our lawyers are investigating Ozempic lawsuits for patients who developed NAION, gastroparesis, or other gastrointestinal conditions like bowel obstruction or cyclic vomiting syndrome.
Ozempic (semaglutide) is a drug for type 2 diabetes, also used for weight management. Recent studies link Ozempic, especially at higher doses, to gastroparesis. The warning label did not initially reflect these risks adequately. Individuals injured after taking Ozempic may be entitled to financial compensation through product liability lawsuits.
Lawsuits involving Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro are now part of an MDL class action lawsuit (as of February 2024). This page provides updates on the Ozempic litigation and potential settlement values.
Our Ozempic lawyers provide the latest updates on this litigation. Check back for new developments.
April 9, 2025
Eli Lilly and Novo Nordisk are attempting to block expert testimony from Dr. Daniel Raines and Dr. Eliot Siegel, who link Ozempic and Mounjaro to gastroparesis. The defense argues that a gastric emptying study is necessary to confirm gastroparesis and that clinical judgment or symptom timing alone are insufficient evidence. This strategy aims to disqualify claims from individuals without formal testing, even if their symptoms strongly suggest the drugs as the cause. Plaintiffs argue this ignores standard medical practice where doctors often rely on symptoms and response to medication cessation, especially for drug-induced conditions. Requiring objective testing in every case could unfairly exclude valid claims.
April 1, 2025
The Ozempic MDL added 164 new cases in March, totaling 1,685 pending lawsuits, following 110 filings in February. The parties are preparing for a Rule 702 hearing on May 14, 2025, to challenge the admissibility of expert testimony on causation, which could significantly impact the types of claims that proceed.
Our lawyers are investigating Ozempic lawsuits for patients who developed NAION, gastroparesis, or other gastrointestinal conditions like bowel obstruction or cyclic vomiting syndrome.
Ozempic (semaglutide) is a drug for type 2 diabetes, also used for weight management. Recent studies link Ozempic, especially at higher doses, to gastroparesis. The warning label did not initially reflect these risks adequately. Individuals injured after taking Ozempic may be entitled to financial compensation through product liability lawsuits.
Lawsuits involving Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro are now part of an MDL class action lawsuit (as of February 2024). This page provides updates on the Ozempic litigation and potential settlement values.
Our Ozempic lawyers provide the latest updates on this litigation. Check back for new developments.
March 26, 2025
A new lawsuit was directly filed into the GLP-1 MDL in Pennsylvania by an Illinois plaintiff alleging that Ozempic caused debilitating gastroparesis. The complaint argues Novo Nordisk knew about the risk but failed to warn patients and doctors. The plaintiff took Ozempic for weight management and suffered severe gastrointestinal complications.
March 17, 2025
Eli Lilly filed a motion requesting that the court mandate contemporaneous objective testing for a reliable gastroparesis diagnosis and exclude expert testimony suggesting diagnosis can be reliable without such testing. Lilly argues this is necessary for medical reliability and to prevent speculative diagnoses, aiming to impose a rigid diagnostic standard that may not reflect real-world medical or tort claim practices. Plaintiffs argue this is an attempt to limit claims by disregarding diagnoses based on symptoms and clinical judgment.
March 5, 2025
The Ozempic MDL added 78 new cases in February, slightly less than January’s 110, bringing the total pending cases to 1,521, potentially indicating a new average monthly volume.
February 26, 2025
A JAMA Ophthalmology study investigated the link between semaglutide and NAION, finding an increased relative incidence among semaglutide users with type 2 diabetes. The authors recommend healthcare providers discuss this potential risk with patients.
February 25, 2025
Eli Lilly & Co. announced a price reduction for its weight-loss and diabetes medication, Zepbound, for self-paying patients and introduced new dosage options, potentially due to sales not meeting expectations amid awareness of risks and limitations.
February 21, 2025
The agenda for the upcoming Case Management Conference includes reviewing case filings, discussing a standardized short form complaint, a coordination order, non-expert deposition protocols, and planning for the Rule 702 hearing on May 14, 2025.
February 6, 2025
The GLP-1 Receptor MDL saw a sharp increase with 110 new lawsuits filed in January, totaling 1,443 pending cases, after a slower December. Our firm continues to receive inquiries from individuals with severe gastrointestinal injuries from GLP-1 receptor agonists like Ozempic.
February 1, 2025
A Michigan woman sued Novo Nordisk, alleging Ozempic caused severe gastrointestinal injuries. The lawsuit claims negligent design, marketing, and failure to warn about risks like gastroparesis and bowel obstruction, detailing the plaintiff’s debilitating symptoms requiring hospitalization after using Ozempic in Texas.
January 29, 2025
Defendants in the Ozempic MDL moved to dismiss secondary claims in the master complaint, but not the core failure-to-warn claims. Plaintiffs argue this is an attempt to narrow the litigation before addressing the main issue of undisclosed gastrointestinal risks.
January 28, 2025
A JAMA Otolaryngology–Head & Neck Surgery study found an increased risk of thyroid cancer within the first year of GLP-1RA therapy, including Ozempic and Mounjaro, compared to other diabetes medications, raising further concerns about the safety of these drugs.
January 22, 2025
A new study highlighted a mix of health outcomes for GLP-1RAs like Ozempic, noting potential benefits but also increased risks of gastrointestinal disorders, kidney stones, arthritis, fainting, and pancreatitis, suggesting the drug may not be as safe as advertised and indicating inadequate warnings.
January 9, 2025
A pivotal Rule 702 evidentiary hearing is scheduled for May 14, 2025, to evaluate the admissibility of expert testimony on causation, a critical step for the litigation. All experts subject to motions to exclude will testify.
January 8, 2025
A status conference is scheduled for next Tuesday.
January 5, 2025
The Ozempic MDL saw a slower growth in December with 31 new cases, totaling 1,331. A May 2025 evidentiary hearing is scheduled to review scientific evidence linking GLP-1 receptor agonists to gastrointestinal injuries.
December 31, 2024
Plaintiffs’ lead counsel anticipates thousands, potentially tens of thousands, of cases will be added to the Ozempic MDL. Judge Marston scheduled an evidentiary hearing for May 20, 2025, on early discovery and motion practice regarding preemption, warning label adequacy, and gastroparesis diagnostic testing standards.
December 20, 2024
The JPML expanded the GLP-1 receptor agonist MDL to include Saxenda claims but rejected adding blood clot-related injuries due to complexity concerns, focusing the MDL on gastrointestinal injuries.
November 20, 2024
Lawyers for Ozempic plaintiffs filed a new master complaint in the MDL, refining allegations against defendants like Novo Nordisk and focusing on claims regarding gastrointestinal injuries and other serious side effects.
November 13, 2024
A Tennessee woman filed a new lawsuit in the GLP-1 RA MDL, alleging Novo Nordisk’s Ozempic and Wegovy caused severe, chronic gastrointestinal injuries, including gastroparesis, supported by an objective gastric emptying study confirming the condition. The lawsuit claims failure to adequately warn about these risks.
November 12, 2024
New filings in the Ozempic MDL focus on allegations that Novo Nordisk systematically downplayed gastroparesis risks in its marketing, aware of the drug’s impact on stomach motility but reluctant to adjust warning labels.
November 7, 2024
Federal regulators issued new warnings for GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, linking them to the risk of pulmonary aspiration during elective surgeries due to slowed stomach emptying.
November 4, 2024
Gastric emptying studies are increasingly important in the GLP-1 agonist litigation as the MDL judge raises questions about proving gastroparesis and its causation by Ozempic. Objective results from these studies are key to substantiating claims.
November 1, 2024
The GLP-1 receptor agonists MDL continues to grow, though at a slower rate, with 131 new cases in October, totaling 1,221. Attorneys are likely tightening criteria for new cases, focusing on well-documented gastroparesis claims.
October 30, 2024
The court issued a new scheduling order with deadlines extending into 2026 for fact discovery, expert reports, depositions, and motions, indicating a long litigation process.
October 29, 2024
The FDA cited Novo Nordisk’s Ozempic and Wegovy production plant for quality control issues regarding water used in production, raising concerns about their prioritization of maximum production and profit.
October 18, 2024
A Louisiana resident filed a new lawsuit alleging severe harm from Ozempic, diagnosed with gastroparesis months after starting the drug in June 2023. The lawsuit claims failure to adequately warn about gastroparesis and other gastrointestinal issues.
October 17, 2024
The MDL judge ruled that early pre-trial discovery will focus on warning label adequacy and federal preemption, denying the plaintiffs’ request to include marketing discovery at this stage, which they argued was relevant to the failure-to-warn claims.
September 29, 2024
Defendants opposed plaintiffs’ request for limited marketing discovery, arguing it’s unnecessary due to the court’s focus on label adequacy and preemption. Plaintiffs contend marketing materials are part of the “label” and relevant to warning adequacy, citing legal precedent.
September 12, 2024
The court scheduled early discovery on preemption and warning label adequacy but is considering plaintiffs’ motion to include marketing discovery, arguing its relevance to how risks were communicated.
September 6, 2024
A Kentucky woman filed a new lawsuit in the MDL alleging severe injuries, including gastroparesis, after using Ozempic from January to April 2023. The lawsuit claims Novo Nordisk failed to adequately warn about gastrointestinal risks and misleadingly marketed the drug.
September 2, 2024
A new study found a potential link between GLP-1 receptor agonists (semaglutide and liraglutide) and increased reports of suicidal thoughts, particularly when semaglutide is used with antidepressants and benzodiazepines, raising concerns about the drug’s safety. Our lawyers are not currently taking suicide lawsuits but may reconsider after further investigation.
September 1, 2024
Plaintiffs’ attorneys urged the judge against ruling on cross-cutting issues without full discovery, emphasizing the need for a detailed examination of evidence using the Bradford Hill criteria to determine causation.
August 27, 2024
We posted a new Ozempic lawsuit video with the latest litigation updates.
August 24, 2024
The court granted the defendants’ request for early discovery and motion practice on the reliability of gastroparesis diagnostic testing and the adequacy of warning labels. A ruling on general causation was deferred.
August 21, 2024
A Kentucky woman filed a new lawsuit seeking damages for severe injuries, including gastroparesis, allegedly caused by Eli Lilly’s Mounjaro and Trulicity, claiming inadequate warnings about the risks.
Our lawyers are investigating Ozempic lawsuits for patients who developed NAION, gastroparesis, or other gastrointestinal conditions like bowel obstruction or cyclic vomiting syndrome.
Ozempic (semaglutide) is a drug for type 2 diabetes, also used for weight management. Recent studies link Ozempic, especially at higher doses, to gastroparesis. The warning label did not initially reflect these risks adequately. Individuals injured after taking Ozempic may be entitled to financial compensation through product liability lawsuits.
Lawsuits involving Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro are now part of an MDL class action lawsuit (as of February 2024). This page provides updates on the Ozempic litigation and potential settlement values.
Our Ozempic lawyers provide the latest updates on this litigation. Check back for new developments.
August 21, 2024
A Kentucky woman filed a lawsuit against Eli Lilly and Company, alleging that Mounjaro and Trulicity caused her to develop gastroparesis. The lawsuit claims failure to adequately warn about the risks of these GLP-1 receptor agonists. The plaintiff states that had she or her doctor been properly informed, she would not have used these medications.
August 15, 2024
Case Management Order No. 17 outlines a 9% common benefit fee and a 2% common benefit expense fund from any gross monetary recovery in the Ozempic MDL, intended to compensate leadership attorneys for work benefiting all plaintiffs. Typically, the attorneys’ fee portion comes from the lawyer’s contingency fee, not the client’s recovery, while the expense fund is usually a separate deduction.
August 11, 2024
A New Hampshire resident filed an Ozempic lawsuit alleging she developed gastroparesis after using the drug for Type 2 diabetes from June 2022 to September 2023. The lawsuit, filed directly in the MDL, claims Novo Nordisk failed to adequately warn about the risks.
August 1, 2024
An Illinois man filed a lawsuit against Novo Nordisk and Eli Lilly, alleging failure to warn about the risks of Ozempic and Mounjaro. He was prescribed Ozempic for diabetes in October 2022, switched to Mounjaro, and was hospitalized in June 2023 with bowel obstruction requiring surgery, which he attributes to the drugs.
July 9, 2024
A new order allows direct filing of Ozempic lawsuits into MDL No. 3094 in the Eastern District of Pennsylvania to improve administrative efficiency. The order also streamlines service processes and limits direct filings to a single plaintiff.
July 8, 2024
The upcoming status conference will address issues from cross-cutting motion briefs, disputed ESI protocol provisions, discovery special master candidates, the status of the time and expense order, the status of discovery, and the cross-cutting motion issue, where defendants often seek to bifurcate discovery on causation, a move typically opposed by MDL judges.
July 3, 2024
A new study found a statistically significant association between semaglutide (including Ozempic) and an increased incidence of NAION, a cause of sudden vision loss, in patients managing diabetes or weight.
June 23, 2024
A Kansas resident sued Ozempic’s manufacturer, alleging the drug caused gastroparesis after using it for type 2 diabetes from November 2019 to October 2022, and seeks damages for their suffering and medical expenses.
June 10, 2024
U.S. District Judge Karen Marston in Philadelphia took over the Ozempic MDL, expected to involve over 10,000 personal injury lawsuits, following the passing of the previous judge. Lawyers are preparing the cases, including developing a plaintiff fact sheet.
May 23, 2024
The passing of MDL Judge Gene E.K. Pratter at age 75 has stalled some momentum in the Ozempic litigation as a new judge needs to be appointed and become familiar with the case.
May 21, 2024
Ozempic plaintiffs’ and defendants’ attorneys are close to agreement on a 13-page Plaintiff Fact Sheet and authorization form to be required from all plaintiffs, with electronic submission handled by a third-party vendor.
April 16, 2024
Plaintiffs’ attorneys refuted the defendants’ argument that novel treatment approaches relieve them of warning responsibilities, emphasizing the necessity of adequate warnings given the drugs’ widespread use and criticizing the labels for inadequately warning of severe risks and the lack of long-term studies. They also advocated for differential diagnosis over solely relying on gastric emptying studies for causation.
April 4, 2024
A dispute arose among plaintiffs’ lawyers regarding leadership positions in the Ozempic litigation, with one firm criticizing the process as unfair and non-transparent, though the current leadership is considered capable.
March 15, 2024
The first status conference in the Ozempic MDL addressed organizational and procedural aspects, including plaintiffs’ leadership, motion practice, and the development of plaintiff fact sheets, with both sides expressing willingness to cooperate on motion handling.
February 8, 2024
New research indicated weight loss with GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro but also a heightened likelihood of gastrointestinal issues, particularly at higher doses, with Mounjaro showing the most potent glycemic control.
February 5, 2024
The MDL Panel consolidated federal lawsuits involving Ozempic and similar medications under a federal judge in Philadelphia, rejecting the defendants’ preferred jurisdictions, noting the presence of numerous cases in the Eastern District of Pennsylvania near Novo Nordisk’s headquarters. Thousands of lawsuits are expected, focusing on failure to warn about gastroparesis risks.
January 8, 2024
A 2024 study in Nature contradicted concerns about suicide risks associated with GLP-1 receptor agonists like Ozempic and Mounjaro, finding no increased risk and suggesting a lower likelihood of suicide attempts in users compared to obese non-users.
January 6, 2024
Novo Nordisk (Ozempic) supported consolidating GLP-1 receptor agonist lawsuits, while Eli Lilly (Mounjaro) opposed inclusion, arguing their products are primarily for type 2 diabetes, not weight loss, and suggesting alternative jurisdictions for the smaller number of cases involving their drugs.
December 1, 2023
A group of plaintiffs filed a motion with the JPML to centralize all federal gastroparesis lawsuits related to Ozempic, Wegovy, Mounjaro, and similar GLP-1 receptor agonist drugs, proposing the Western District of Louisiana for pretrial proceedings.
November 7, 2023
Novo Nordisk is facing a class action lawsuit in Canada alleging insufficient warnings about the potential for gastroparesis caused by Ozempic, mirroring lawsuits in the U.S.
October 6, 2023
A new study in JAMA suggested an increased risk of severe gastrointestinal issues in individuals using weight loss medications like Ozempic or Wegovy, providing more evidence for a potential association with GLP-1 agonists.
July 25, 2023
Newly released evidence indicated that using Ozempic or Wegovy for weight loss can cause severe gastrointestinal conditions, including gastroparesis and cyclic vomiting syndrome, particularly with prolonged use at high doses.
Our lawyers are investigating Ozempic lawsuits for patients who developed NAION, gastroparesis, or other gastrointestinal conditions like bowel obstruction or cyclic vomiting syndrome.
Ozempic (semaglutide) is a prescription medication for type 2 diabetes, also used for weight management. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, mimicking a hormone that regulates blood sugar. While approved for diabetes, its weight loss effects have led to off-label prescriptions for obesity. A higher-dose version is sold as Wegovy. Ozempic is manufactured by Novo Nordisk.
Ozempic, developed in 2012 and approved in the U.S. in 2017, stimulates insulin production and slows digestion, helping control blood sugar. It is a once-weekly injection. The weight loss observed in trials led to the approval of higher-dose semaglutide (Wegovy) for chronic weight management. The central question in the lawsuits is whether the manufacturer adequately warned about the risks, particularly for those using it for weight loss.
Gastroparesis is a condition where the stomach muscles don’t move food properly through the digestive system, leading to nausea, vomiting, pain, bloating, dehydration, feeling full quickly, acid reflux, fluctuating blood sugar, loss of appetite, weight loss, malnutrition, and reduced quality of life. There is no known cure. The chronic and often misunderstood nature of gastroparesis can be physically and psychologically devastating for sufferers.
Cholecystitis, or inflammation of the gallbladder, often caused by blockage from gallstones, is a serious condition requiring immediate treatment, typically gallbladder removal. Gallstones are hard deposits, either cholesterol or pigment stones. Living with cholecystitis involves unpredictable and excruciating pain, nausea, vomiting, and fever.
The lawsuits argue that the development of cholecystitis or gastroparesis could have been avoided if the medication had proper warnings about these risks. Plaintiffs contend that drug makers have a duty to fully disclose potential risks to allow patients to make informed healthcare decisions.
In 2024, NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a condition causing sudden vision loss due to blocked blood flow to the optic nerve, emerged as a potential Ozempic side effect. While typically linked to other risk factors, a new study suggests a connection to Ozempic, possibly due to rapid blood glucose fluctuations affecting optic nerve blood flow in susceptible individuals. Our firm is investigating these cases, believing they could result in substantial settlements due to the severity of vision loss.
Estimating settlement value is difficult early in litigation. For “top tier” Ozempic cases involving severe gastroparesis or death, an estimated settlement range is $400,000 to $700,000, based on assumptions about causation evidence. Cases with less severe injuries are expected to have lower settlement payouts.
The significant profits from Ozempic and related drugs may incentivize the manufacturers to settle claims to protect their reputation and continued sales, potentially offering substantial payouts to avoid adverse publicity and large verdicts.
Settlement amounts for Ozempic weight loss cases may be higher than for diabetes cases due to factors like a potentially younger patient demographic experiencing longer-term impacts, a higher perceived duty of care for lifestyle medications, and potentially clearer causation due to fewer underlying health issues. Jurors may also view a failure to warn for a weight loss drug as more egregious, potentially leading to larger punitive damages.
On September 28, 2023, the FDA added a new warning to the Ozempic label about the potential for increased risk of ileus, a bowel blockage, advising patients experiencing symptoms to contact their healthcare provider immediately and recommending monitoring by healthcare providers.
Every Ozempic lawsuit claims that Novo Nordisk failed to provide adequate warnings about the risk of developing gastroparesis. While the label mentions common GI side effects, it does not link them to gastroparesis or include gastroparesis in the “Warnings and Precautions” section. Plaintiffs argue that Novo Nordisk was or should have been aware of this risk based on clinical data and medical literature and that this failure to warn affected prescribing decisions. The risk of gastroparesis is also noted across the GLP-1RA drug class. The lawsuits contend that adequate disclosure of this risk would have influenced prescribing and monitoring.
In February 2024, an Ozempic MDL (multidistrict litigation) was certified, which consolidates similar cases for streamlined pretrial proceedings. While often referred to as a class action, in an MDL, each plaintiff retains their individual lawsuit. The goal is to increase efficiency and potentially lead to quicker settlements through higher negotiation leverage. Settlement amounts will likely vary based on injury severity and evidence.
Estimating settlement value is difficult early in litigation. For “top tier” Ozempic cases involving severe gastroparesis or death, an estimated settlement range is $400,000 to $700,000, based on assumptions about causation evidence. Cases with less severe injuries are expected to have lower settlement payouts.
The significant profits from Ozempic and related drugs may incentivize the manufacturers to settle claims to protect their reputation and continued sales, potentially offering substantial payouts to avoid adverse publicity and large verdicts.
Settlement amounts for Ozempic weight loss cases may be higher than for diabetes cases due to factors like a potentially younger patient demographic experiencing longer-term impacts, a higher perceived duty of care for lifestyle medications, and potentially clearer causation due to fewer underlying health issues. Jurors may also view a failure to warn for a weight loss drug as more egregious, potentially leading to larger punitive damages.
The timeline for settling the Ozempic gastroparesis lawsuit is uncertain and likely years away, as the MDL is in early pretrial proceedings focused on general causation. Factors like bellwether trial outcomes will influence potential payouts. Affected individuals should stay updated on the litigation’s progress.
If you have an Ozempic gastroparesis lawsuit, call our Ozempic lawsuit lawyers today or reach out to Class Action Lawsuiit online for a free consultation.
